Ciprofibrate

Research use only, not for human use.

Ciprofibrate is a peroxisome proliferator-activated receptor agonist.

Ciprofibrate is a peroxisome proliferator-activated receptor agonist. It was reported that ciprofibrate decreased the levels of plasma triglycerides and total cholesterol as well as low-density lipoprotein cholesterol. Meanwhile, ciprofibrate elevated plasma levels of high-density lipoprotein cholesterol. (In Vitro):Ciprofibrate (500 μM; 4 hours) increases the PPARa phosphorylation level in rat Fao cells.In a LucLite assay, Ciprofibrate (10-100μM; 24 hours) induces PPARR activation by existing increased LUC activities in the rat liver H4IIEC3 cells transfected with PPRE-AB LUC reporter gene plasmid.Ciprofibrate (10-100 μM; 24 hours) is not cytotoxic for HepG2 cells, and the cell viability is 99.7%.Ciprofibrate (100 μM; 24 hours) also abolishes FFAs mixture-induced lipid deposition and decreases FFAs mixture-increased TG contents in HepG2 cells.Ciprofibrate (100 μM; 24 hours) almost entirely eliminates the FFAs mixture-induced inflammatory cytokines overproduction, including MCP-1, TNF-α, and IL-6 in HepG2 cells.(In Vivo):Ciprofibrate (oral administration; 10 mg/kg/day; 3 days) does not result in any significant effects on body weight or absolute liver weight for MCD diet-fed mice. Ciprofibrate improves hepatic steatosis and reduced hepatic necro-inflammation in MCD diet-fed mice. It also reduced hepatic cytokine protein and mRNA levels (MCP-1, TNFα and IL-6) as compared to those of choline-deficient (MCD) diet-fed mice.

Ciprofibrate (500 μM; 4 hours) increases the PPARa phosphorylation level in rat Fao cells.In a LucLite assay, Ciprofibrate (10-100μM; 24 hours) induces PPARR activation by existing increased LUC activities in the rat liver H4IIEC3 cells transfected with PPRE-AB LUC reporter gene plasmid.Ciprofibrate (10-100 μM; 24 hours) is not cytotoxic for HepG2 cells, and the cell viability is 99.7%.Ciprofibrate (100 μM; 24 hours) also abolishes FFAs mixture-induced lipid deposition and decreases FFAs mixture-increased TG contents?in HepG2 cells.Ciprofibrate (100 μM; 24 hours) almost entirely eliminates the FFAs mixture-induced inflammatory cytokines overproduction, including MCP-1, TNF-α, and IL-6 in HepG2 cells.

Ciprofibrate (oral administration; 10 mg/kg/day; 3 days) does not result in any significant effects on body weight or absolute liver weight for MCD diet-fed mice. Ciprofibrate improves hepatic steatosis and reduced hepatic necro-inflammation in MCD diet-fed mice. It also reduced hepatic cytokine protein and mRNA levels (MCP-1, TNFα and IL-6) as compared to those of ?choline-deficient (MCD) diet-fed mice. Animal Model:C57BL/6 mice (six-week-old males)Dosage:10 mg/kg Administration:Oral administration; 10 mg/kg/day; 3 days Result:Decreased MCD diet-resulted hepatic steatosis and hepatic necro-inflammation in mice.

(±)-Ciprofibrate | WIN 35,833

Metabolic Enzyme/Protease

PPAR

PPAR

Cancer

——

52214-84-3

289.16

C13H14Cl2O3

>98% (HPLC)

Soluble in DMSO

CC(C)(OC1=CC=C(C2C(Cl)(Cl)C2)C=C1)C(O)=O

2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoic acid

(-20℃)

With Ice Pack

≥ 2 years